These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15963388)

  • 1. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
    Pfützner A; Marx N; Lübben G; Langenfeld M; Walcher D; Konrad T; Forst T
    J Am Coll Cardiol; 2005 Jun; 45(12):1925-31. PubMed ID: 15963388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
    Langenfeld MR; Forst T; Hohberg C; Kann P; Lübben G; Konrad T; Füllert SD; Sachara C; Pfützner A
    Circulation; 2005 May; 111(19):2525-31. PubMed ID: 15883215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
    JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.
    Forst T; Hohberg C; Fuellert SD; Lübben G; Konrad T; Löbig M; Weber MM; Sachara C; Gottschall V; Pfützner A
    Horm Metab Res; 2005 Aug; 37(8):521-7. PubMed ID: 16138267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
    Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
    Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.
    Pfützner A; Hohberg C; Lübben G; Pahler S; Pfützner AH; Kann P; Forst T
    Horm Metab Res; 2005 Aug; 37(8):510-5. PubMed ID: 16138265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
    Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study.
    Hohberg C; Pfützner A; Forst T; Lübben G; Karagiannis E; Borchert M; Schöndorf T
    Diabetes Obes Metab; 2009 May; 11(5):464-71. PubMed ID: 19422402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus.
    Park JS; Cho MH; Lee KY; Kim CS; Kim HJ; Nam JS; Ahn CW; Cha BS; Lim SK; Kim KR; Lee HC
    Metabolism; 2007 Aug; 56(8):1081-6. PubMed ID: 17618953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
    Polonsky T; Mazzone T; Davidson M
    Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    Kodama N; Tahara N; Tahara A; Honda A; Nitta Y; Mizoguchi M; Kaida H; Ishibashi M; Abe T; Ikeda H; Narula J; Fukumoto Y; Yamagishi S; Imaizumi T
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4438-45. PubMed ID: 24030946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial.
    Christoph M; Herold J; Berg-Holldack A; Rauwolf T; Ziemssen T; Schmeisser A; Weinert S; Ebner B; Ibrahim K; Strasser RH; Braun-Dullaeus RC
    Cardiology; 2015; 131(3):165-71. PubMed ID: 25967848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS).
    Wagenknecht LE; D'Agostino R; Savage PJ; O'Leary DH; Saad MF; Haffner SM
    Stroke; 1997 May; 28(5):999-1005. PubMed ID: 9158641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes.
    Leinonen ES; Hiukka A; Hurt-Camejo E; Wiklund O; Sarna SS; Mattson Hultén L; Westerbacka J; Salonen RM; Salonen JT; Taskinen MR
    J Intern Med; 2004 Aug; 256(2):119-27. PubMed ID: 15257724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
    Pfützner A; Schöndorf T; Seidel D; Winkler K; Matthaei S; Hamann A; Forst T
    Metabolism; 2006 Jan; 55(1):20-5. PubMed ID: 16324915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.